OTCPK:ACHF.F

Stock Analysis Report

Executive Summary

Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Risks

  • Arch Biopartners is not covered by any analysts.

Share Price & News

How has Arch Biopartners's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-17.4%

OTCPK:ACHF.F

-0.5%

US Life Sciences

-1.0%

US Market


1 Year Return

-39.3%

OTCPK:ACHF.F

10.4%

US Life Sciences

-0.4%

US Market

ACHF.F underperformed the Life Sciences industry which returned 10.4% over the past year.

ACHF.F underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

ACHF.FIndustryMarket
7 Day-17.4%-0.5%-1.0%
30 Day-7.2%-4.9%-3.3%
90 Day-9.3%3.2%0.8%
1 Year-39.3%-39.3%10.6%10.4%1.9%-0.4%
3 Yearn/a70.1%68.7%39.4%30.4%
5 Yearn/a110.3%100.3%54.2%37.1%

Price Volatility Vs. Market

How volatile is Arch Biopartners's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Arch Biopartners undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Arch Biopartners is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Arch Biopartners has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ACHF.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Arch Biopartners regulatory filings here.
  • Explore potentially undervalued companies in the pharmaceuticals & biotech industry.

Future Growth

How is Arch Biopartners expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.3%

Forecasted Life Sciences industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Arch Biopartners has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Arch Biopartners performed over the past 5 years?

-44.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Arch Biopartners does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Arch Biopartners's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Arch Biopartners's 1-year growth to the US Life Sciences industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Arch Biopartners has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Arch Biopartners has efficiently used its assets last year compared to the US Life Sciences industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Arch Biopartners improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Arch Biopartners's financial position?


Financial Position Analysis

Arch Biopartners's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Arch Biopartners's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Arch Biopartners has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Arch Biopartners's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Arch Biopartners has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Arch Biopartners has less than a year of cash runway based on current free cash flow.

Arch Biopartners has less than a year of cash runway if free cash flow continues to grow at historical rates of 51% each year.


Next Steps

Dividend

What is Arch Biopartners's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Arch Biopartners's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Arch Biopartners's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Arch Biopartners has not reported any payouts.

Unable to verify if Arch Biopartners's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Arch Biopartners has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Arch Biopartners's salary, the management and board of directors tenure and is there insider trading?

9.3yrs

Average board tenure


CEO

Richard Muruve (48yo)

10.0yrs

Tenure

CA$100,000

Compensation

Mr. Richard Gabriel Muruve is a Co-Founder of Arch Biopartners Inc. and has been its Chief Executive Officer since August 2009 and serves as its President May 12, 2010. Mr. Muruve served as Acting Chief Fi ...


CEO Compensation Analysis

Richard's remuneration is lower than average for companies of similar size in United States of America.

Richard's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

9.3yrs

Average Tenure

58yo

Average Age

The tenure for the Arch Biopartners board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Richard Muruve (48yo)

    Co-Founder

    • Tenure: 10.0yrs
    • Compensation: CA$100.00k
  • Dan Muruve

    Co-Founder

  • Justin MacDonald

    Co-Founder & Principal Scientist

  • Paul Beck

    Co-Founder & Principal Scientist

  • Andrew Bishop (53yo)

    Acting CFO & Director


Board Members

  • Richard Rossman (74yo)

    Director

    • Tenure: 9.3yrs
  • Andrew Bishop (53yo)

    Acting CFO & Director

    • Tenure: 9.3yrs
  • Patrick Vink (56yo)

    Director

    • Tenure: 2.7yrs
  • Conor Gunne (67yo)

    Director

    • Tenure: 9.3yrs
  • Richard Muruve (48yo)

    Co-Founder

    • Tenure: 14.0yrs
    • Compensation: CA$100.00k
  • Claude Allary

    Director

    • Tenure: 5.3yrs
  • Adrian Haigh (60yo)

    Director

    • Tenure: 5.0yrs
  • Hindrik Mulder

    Member of Scientific Advisory Board

  • Robert Hodges

    Member of Scientific Advisory Board

  • Dan Muruve

    Co-Founder

Company Information

Arch Biopartners Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Arch Biopartners Inc.
  • Ticker: ACHF.F
  • Exchange: OTCPK
  • Founded:
  • Industry: life sciences tools and services
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$48.496m
  • Shares outstanding: 58.71m
  • Website: Click here

Location

  • Arch Biopartners Inc.
  • 545 King Street West
  • Toronto
  • Ontario
  • M5V 1M1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ACHF.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMay 2010
ARCHTSXV (TSX Venture Exchange)YesCommon SharesCACADMay 2010

Biography

Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant lung and u ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 00:39
End of Day Share Price2019/08/16 00:00
Earnings2019/03/31
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.